ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M

ADC Therapeutics SA

PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.
Preliminary Q3 2025 ZYNLONTA net product revenue approximately $15.8M.
Cash and equivalents $234.7M as of Sep 30; pro forma $292.3M after PIPE net proceeds (~$57.6M).
PIPE led by TCGX with Redmile Group and other existing investors; Jefferies acted as placement agent.
Net proceeds to fund ZYNLONTA commercial expansion, strengthen balance sheet, and working capital.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

ADC Therapeutics SA issued 11,250,000 common shares of common stock to certain institutional investors for $4.00 per share.

Security: common stock
Shares: 11,250,000 common shares
Purchaser: certain institutional investors
Consideration: $4.00 per share

Exact text from the filing

On October 12, 2025, ADC Therapeutics SA (the “Company”) entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private placement. In the private placement, the Company will sell 11,250,000 common shares at $4.00 per share

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

ADC Therapeutics SA issued pre-funded warrants to purchase 3,846,153 common shares of warrant to certain institutional investors for $3.90 per pre-funded warrant.

Security: warrant
Shares: pre-funded warrants to purchase 3,846,153 common shares
Purchaser: certain institutional investors
Consideration: $3.90 per pre-funded warrant

Exact text from the filing

and pre-funded warrants to purchase 3,846,153 common shares at $3.90 per pre-funded warrant

View on SEC.gov

Browse all equity issuances →

ADC Therapeutics SA filing history →

Source: SEC EDGAR

accession 0000950103-25-013103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.